Zafgen falls on more beloranib news

Zafgen (NASDAQ:ZFGN) plunged $10.66 (51%) to $10.36 on Friday after disclosing the Prader-Willi syndrome patient who died in the Phase III bestPWS (ZAF-311) trial was receiving the company's beloranib ( ZGN-440) and not placebo. The company said it still does not know the cause of the patient death.

The company also said FDA placed a partial clinical hold on beloranib. Zafgen said bestPWS will now screen patients for existing thrombotic disease and will monitor patients for the development of thrombotic disease. ...